<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03672630</url>
  </required_header>
  <id_info>
    <org_study_id>18819</org_study_id>
    <secondary_id>PCS-2017C2-7764</secondary_id>
    <nct_id>NCT03672630</nct_id>
  </id_info>
  <brief_title>Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease</brief_title>
  <acronym>MAC2v3</acronym>
  <official_title>Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kevin Winthrop</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Jewish Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center at Tyler</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Louisiana State University Health Sciences Center in New Orleans</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kansas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vancouver Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temple University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loma Linda University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      NTM therapy consists of a multi-drug macrolide based regimen for 18-24 months. Treated
      patients frequently experience debilitating side effects, and many patients delay the start
      of antibiotic treatment due to these risks. Common side effects include nausea, diarrhea, and
      fatigue, and rare but serious toxicities include ocular toxicity, hearing loss, and
      hematologic toxicity. To date, most of the evidence underlying the current treatment
      recommendations has come from observational studies in which either a macrolide has been
      combined with rifampin and ethambutol, or in some cases combined with ethambutol alone. The
      proposed study will answer whether a third drug is necessary or whether taking two drugs can
      increase tolerability without a substantial loss of efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mycobacterium avium complex (MAC) are a subset of nontuberculous mycobacteria (NTM),
      environmental bacteria that can cause chronic, debilitating pulmonary disease, primarily
      affecting those over age 60. The goals of treatment are to improve symptoms, stop disease
      progression, and clear the infection. We propose to address a longstanding controversy in the
      therapy of pulmonary MAC disease, whether patients must take three antibiotics concomitantly,
      or if two are sufficient. The study is a multicenter randomized pragmatic clinical trial to
      compare azithromycin + ethambutol (2-drug therapy) vs. azithromycin + ethambutol + rifampin
      (3-drug therapy) for non-cavitary pulmonary MAC disease. All clinical outcomes will be
      considered standard of care and abstracted from clinical records. Therapy changes and adverse
      events will be recorded at routine visits. Health-related quality of life (HRQoL) and
      self-reported toxicity will be captured centrally in a web-based database, and CT scans will
      be read centrally. Co-primary outcomes are culture conversion and tolerability of treatment.
      The primary analysis for culture conversion will be conducted as a per-protocol
      non-inferiority analysis, and the primary analysis for tolerability will be conducted as an
      intention-to-treat superiority analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2019</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acid-fast bacilli (AFB) culture negativity</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Two consecutive negative AFB cultures by 12 months post randomization without reversion to positive</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapy completion</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>The proportion of patients who complete 12 months of therapy on their assigned regimen with &quot;satisfactory adherence&quot;. &quot;Satisfactory adherence&quot; is defined as taking 80% of their prescribed doses/not missing more than 75 days of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QOL-B Respiratory Symptoms Score</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Quality of Life-Bronchiectasis (QOL-B) with NTM module The QOL-B is a self-administered questionnaire that has been validated in patients with bronchiectasis. The questionnaire measures 8 separate domains: Physical Functioning, Role Functioning, Vitality, Emotional Functioning, Social Functioning, Treatment Burden, Health Perceptions, and Respiratory Symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NTM Symptoms Score</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Quality of Life-Bronchiectasis (QOL-B) with NTM module The QOL-B is a self-administered questionnaire that has been validated in patients with bronchiectasis. The NTM module includes 4 additional domains: Eating Problems, Body Image, Digestive Symptoms, and NTM Symptoms. No total score is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue AE proportion</measure>
    <time_frame>Cumulative to 12 months</time_frame>
    <description>Self-report, Moderate or worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal AE proportion</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Self-report, Moderate or worse: Nausea, diarrhea, decreased appetite, OR abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver AE proportion</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Laboratory grade 2 or higher abnormality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrolide resistance</measure>
    <time_frame>12 months post randomization</time_frame>
    <description>Susceptibility at last positive culture</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Mycobacterium Avium Complex</condition>
  <condition>Nontuberculous Mycobacterium Infection</condition>
  <arm_group>
    <arm_group_label>2-drug regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3-drug regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin 500 MG Oral Tablet [ZITHROMAX]</description>
    <arm_group_label>2-drug regimen</arm_group_label>
    <arm_group_label>3-drug regimen</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethambutol</intervention_name>
    <description>Ethambutol 25 mg/kg [MYAMBUTOL]</description>
    <arm_group_label>2-drug regimen</arm_group_label>
    <arm_group_label>3-drug regimen</arm_group_label>
    <other_name>Myambutol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Rifampin 600 MG [RIFADIN]</description>
    <arm_group_label>3-drug regimen</arm_group_label>
    <other_name>Rifadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Culture positive pulmonary MAC meeting ATS/IDSA disease criteria

          -  Age over 18 years

          -  Ability to provide informed consent

        Exclusion Criteria:

          -  Fibrocavitary disease

          -  Planned surgery for MAC disease

          -  Prior multi-drug therapy for pulmonary NTM

          -  Cystic fibrosis

          -  HIV

          -  History of solid organ or hematologic transplant

          -  Significant drug-drug interaction not clinically manageable in the opinion of the
             investigator

          -  Contraindication to any component of the study treatment regimen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Henkle, PhD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin L Winthrop, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andie Hendrick</last_name>
    <phone>503-494-2136</phone>
    <email>hendrmic@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Megan E Wardrop, MS</last_name>
    <phone>503-346-3752</phone>
    <email>wardrop@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Furukawa, MD</last_name>
      <phone>909-558-4000</phone>
      <phone_ext>47745</phone_ext>
      <email>BFurukawa@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Brian Furukawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deyna Arellano</last_name>
      <phone>858-822-2916</phone>
      <email>daarellano@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Wael ElMaraachli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Merrifield, RN, BSN</last_name>
      <phone>415-206-3509</phone>
      <email>Cindy.Merrifield@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Payam Nahid, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan S. Jacobs, RN, MS</last_name>
      <phone>650-725-8083</phone>
      <email>ssjpulm@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Ruoss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrah Levin, MPH</last_name>
      <phone>303-398-1407</phone>
      <email>levina@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Charles L Daley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Fraczkiewicz, RN</last_name>
      <phone>203-785-3490</phone>
      <email>Lindsey.Fraczkiewicz@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Dela Cruz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amen Hamed</last_name>
      <phone>202-444-0895</phone>
      <email>Amen.Hamed@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Anne O'Donnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shweta Kambali, MBBS, MPH</last_name>
      <email>sxk1020@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Mehdi Mirsaeidi, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Cox</last_name>
      <phone>404-251-1705</phone>
      <email>elizabeth.m.cox@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Colin Swenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spring A. Maleckar</last_name>
      <phone>773-834-4053</phone>
      <email>smaleckar@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela McShane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Keating</last_name>
      <phone>319-356-3241</phone>
      <email>Janet-keating@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Douglas Hornick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Waller, MD</last_name>
      <phone>913-588-2379</phone>
      <email>swaller@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Matthias Salathe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Waller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Schmid, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louisina State University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Lapinel, MD</last_name>
      <phone>504-568-2706</phone>
      <email>nlapin@lsuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Juzar Ali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicole Lapinel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Nguyen, MS</last_name>
      <phone>443-287-6283</phone>
      <email>j.nguyen@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Keira Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Hammel, MA</last_name>
      <phone>507-293-3316</phone>
      <email>hammel.laura@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy Aksamit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcia Epstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marcia Epstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Lau</last_name>
      <phone>646-754-4679</phone>
      <email>Stephanie.Lau@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Doreen Addrizzo-Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela DiMango, MD</last_name>
      <phone>212-305-5730</phone>
    </contact>
    <investigator>
      <last_name>Angela Dimango, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya K Capps</last_name>
      <phone>984-974-2963</phone>
      <email>sonya_capps@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Peader Noone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniels Leigh Anne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andie Hendrick</last_name>
      <phone>503-494-2136</phone>
      <email>hendrmic@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Kevin Winthrop, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Salerno, MD, MS</last_name>
      <phone>215-707-1359</phone>
      <email>breathe@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Salerno, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abbey Grady, MPH</last_name>
      <phone>843-792-2072</phone>
      <email>gradyabi@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Flume, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebekah Hibbard, BS</last_name>
      <phone>903-877-8246</phone>
      <email>rebekah.hibbard@uthct.edu</email>
    </contact>
    <investigator>
      <last_name>David E Griffith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Horne, MD, MPH</last_name>
      <phone>206-744-4689</phone>
      <email>dhorne@uw.edu</email>
    </contact>
    <investigator>
      <last_name>David Horne, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver Clinic</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98664</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mattison Martin, BS</last_name>
      <phone>360-397-3388</phone>
      <email>research@tvc.org</email>
    </contact>
    <investigator>
      <last_name>Nicholas Wysham, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Saddler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chris Saddler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Henkle E, Hedberg K, Schafer S, Novosad S, Winthrop KL. Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012. Ann Am Thorac Soc. 2015 May;12(5):642-7. doi: 10.1513/AnnalsATS.201412-559OC.</citation>
    <PMID>25692495</PMID>
  </reference>
  <reference>
    <citation>Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, Olivier KN. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med. 2010 Oct 1;182(7):970-6. doi: 10.1164/rccm.201002-0310OC. Epub 2010 Jun 10.</citation>
    <PMID>20538958</PMID>
  </reference>
  <reference>
    <citation>Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med. 2010 Oct 1;182(7):977-82. doi: 10.1164/rccm.201003-0503OC. Epub 2010 May 27.</citation>
    <PMID>20508209</PMID>
  </reference>
  <reference>
    <citation>Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ Jr, Winthrop K; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007 Feb 15;175(4):367-416. Review. Erratum in: Am J Respir Crit Care Med. 2007 Apr 1;175(7):744-5. Dosage error in article text.</citation>
    <PMID>17277290</PMID>
  </reference>
  <reference>
    <citation>Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005 Jul 15;172(2):250-3. Epub 2005 Apr 28.</citation>
    <PMID>15860751</PMID>
  </reference>
  <reference>
    <citation>Lee H, Sohn YM, Ko JY, Lee SY, Jhun BW, Park HY, Jeon K, Kim DH, Kim SY, Choi JE, Moon IJ, Shin SJ, Park HJ, Koh WJ. Once-daily dosing of amikacin for treatment of Mycobacterium abscessus lung disease. Int J Tuberc Lung Dis. 2017 Jul 1;21(7):818-824. doi: 10.5588/ijtld.16.0791.</citation>
    <PMID>28633708</PMID>
  </reference>
  <reference>
    <citation>Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004 Jun 1;38(11):1538-44. Epub 2004 May 5.</citation>
    <PMID>15156439</PMID>
  </reference>
  <reference>
    <citation>Winthrop KL, Ku JH, Marras TK, Griffith DE, Daley CL, Olivier KN, Aksamit TR, Varley CD, Mackey K, Prevots DR. The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease. Eur Respir J. 2015 Apr;45(4):1177-9. doi: 10.1183/09031936.00169114. Epub 2015 Jan 22.</citation>
    <PMID>25614169</PMID>
  </reference>
  <reference>
    <citation>Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, Yamada T, Masuda M, Inui N, Chida K, Suda T, Hayakawa H. Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc. 2014 Jan;11(1):23-9. doi: 10.1513/AnnalsATS.201308-266OC.</citation>
    <PMID>24298907</PMID>
  </reference>
  <reference>
    <citation>Griffith DE, Adjemian J, Brown-Elliott BA, Philley JV, Prevots DR, Gaston C, Olivier KN, Wallace RJ Jr. Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med. 2015 Sep 15;192(6):754-60. doi: 10.1164/rccm.201503-0444OC.</citation>
    <PMID>26068042</PMID>
  </reference>
  <reference>
    <citation>Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med. 2007 Jan;101(1):130-8. Epub 2006 Jun 5.</citation>
    <PMID>16750618</PMID>
  </reference>
  <reference>
    <citation>Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest. 2014 Aug;146(2):276-282. doi: 10.1378/chest.13-2538.</citation>
    <PMID>24457542</PMID>
  </reference>
  <reference>
    <citation>Adjemian J, Prevots DR, Gallagher J, Heap K, Gupta R, Griffith D. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc. 2014 Jan;11(1):9-16. doi: 10.1513/AnnalsATS.201304-085OC.</citation>
    <PMID>24236749</PMID>
  </reference>
  <reference>
    <citation>Koh WJ, Moon SM, Kim SY, Woo MA, Kim S, Jhun BW, Park HY, Jeon K, Huh HJ, Ki CS, Lee NY, Chung MJ, Lee KS, Shin SJ, Daley CL, Kim H, Kwon OJ. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J. 2017 Sep 27;50(3). pii: 1602503. doi: 10.1183/13993003.02503-2016. Print 2017 Sep.</citation>
    <PMID>28954780</PMID>
  </reference>
  <reference>
    <citation>Hernán MA, Robins JM. Per-Protocol Analyses of Pragmatic Trials. N Engl J Med. 2017 Oct 5;377(14):1391-1398. doi: 10.1056/NEJMsm1605385.</citation>
    <PMID>28976864</PMID>
  </reference>
  <reference>
    <citation>Murray EJ, Hernán MA. Adherence adjustment in the Coronary Drug Project: A call for better per-protocol effect estimates in randomized trials. Clin Trials. 2016 Aug;13(4):372-8. doi: 10.1177/1740774516634335. Epub 2016 Mar 7.</citation>
    <PMID>26951361</PMID>
  </reference>
  <reference>
    <citation>White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011 Feb 20;30(4):377-99. doi: 10.1002/sim.4067. Epub 2010 Nov 30.</citation>
    <PMID>21225900</PMID>
  </reference>
  <reference>
    <citation>U.S. Food and Drug Administration. FDA Guideline: Evaluation of Gender Differences in Clinical Investigations - Information Sheet, July 22, 1993. Found at https://www.fda.gov/RegulatoryInformation/Guidances/ucm126552.htm. Last accessed 6/11/18.</citation>
  </reference>
  <reference>
    <citation>Henkle E, Novosad S, Siegel SA, Varley CD, Stadnik A, Winthrop KL. Northwest Biorepository of Nontuberculous Mycobacteria Patients- Baseline Characteristics. B25 NON-TUBERCULOUS MYCOBACTERIA: EPIDEMIOLOGY, DIAGNOSIS, AND TREATMENT: American Thoracic Society; 2016. p. A3018-A.</citation>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Kevin Winthrop</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>NTM</keyword>
  <keyword>MAC</keyword>
  <keyword>mycobacteria</keyword>
  <keyword>nontuberculous mycobacteria</keyword>
  <keyword>azithromycin</keyword>
  <keyword>ethambutol</keyword>
  <keyword>rifampin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycobacterium Infections</mesh_term>
    <mesh_term>Mycobacterium avium-intracellulare Infection</mesh_term>
    <mesh_term>Mycobacterium Infections, Nontuberculous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A Full Data Package will be made available in a PCORI-designated repository. The Full Data Package includes the Analyzable Data Set, Full Protocol, metadata, data dictionary, full statistical analysis plan (including all amendments and all documentation for additional work processes), and analytic code from the PCORI-funded research project. The Analyzable Dataset includes a final cleaned and locked data set that contains all the data used in conducting the analyses reported in the PCORI Final Research Report and is de-identified in accordance with the HIPAA Privacy Rule (45 C.F.R. § 164.514(b)).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>The dataset will be available after completion of the study and publication of results.</ipd_time_frame>
    <ipd_access_criteria>Third party data requests will be reviewed by a committee, and approved requests will require a DUA.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

